Macular telangiectasia cell therapy meets primary endpoint in phase 3 trial

WAILEA, Hawaii —NT-501, an encapsulated cell therapy for the treatment of macular telangiectasia type 2, met its primary endpoint across two phase 3 trials, according to a speaker at Retina 2024.
“Treatment with NT-501 vs. sham preserved photoreceptors in patients with MacTel 2, thus meeting the primary endpoint,” Jiong Yan, MD, said.
The NTMT-03-A and NTMT-03-B trials randomized patients 1:1 to treatment with NT-501 (revakinagene taroretcel, Neurotech Pharmaceuticals) or sham to investigate the cell therapy’s efficacy and safety. The trials involved 115 and 113

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart